The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for InfuSystem Holdings Inc. To summarize, we found that InfuSystem Holdings Inc ranked in the 5th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of InfuSystem Holdings Inc, consider:
The stock's equity weight, or the proportion of capital from equity relative to debt, is 90. Notably, its equity weight is greater than 59.47% of US equities in the Healthcare sector yielding a positive free cash flow.
The company's compound free cash flow growth rate over the past 5.69 years comes in at -0.18%; that's greater than merely 9.18% of US stocks we're applying DCF forecasting to.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of InfuSystem Holdings Inc? See PHG, CTLT, PPD, STAA, and AGHC.
Craig-Hallum initiated InfuSystem ([[INFU]] +3.3%) with a Buy rating and $28 price target (indicating upside of 93% from current levels).Analyst Alexander Nowak Nowak argues that the $300M market-cap company selling a one at-home chemotherapy product line, can become a $1B+ company as it plans to add pain management and negative...